BSH 2023 | Advances in the management of fit adults with AML
Steven Knapper, MRCP, FRCPath, DM, Cardiff University, Cardiff, UK, discusses advances that have been made in the treatment and management of fit adults with acute myeloid leukemia (AML), commenting on the value of combining intensive chemotherapy with novel agents including FLT3 inhibitors and gemtuzumab ozogamicin (GO). Prof. Knapper also highlights findings from the AML18 (NCT02272478) and AML19 (ISRCTN78449203) trials, which have demonstrated the value of combining FLAG-Ida with GO in NPM1-mutated AML, and concludes by commenting on the importance of developing strategies for future cooperative trials. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: advisory board
Astellas: advisory board, speakers’ bureau
Jazz: advisory board membership, speakers’ bureau
Novartis: research funding, speakers’ bureau
Pfizer: advisory board, speakers’ bureau
Servier: advisory board, support for conference attendance
